Analyzing the Impact of Lower Medicare Advantage SNF Utilization Rates

The headline matters for nursing home operators because SNF volume is tied to referral pipelines, authorization workload, staffing assumptions, and reimbursement exposure. The available material, however, does not provide the underlying utilization figures or explain why the difference exists.

The signal is operational, not yet a complete financial finding

A lower SNF-use rate among Medicare Advantage beneficiaries should not be treated as proof of a single coverage or access problem. The source record does not identify the time period, beneficiary denominator, acuity levels, or services included in the MedPAC comparison. It also does not establish whether the gap reflects plan design, referral patterns, prior authorization, beneficiary choice, discharge practices, or another factor.

That missing context is material. A facility cannot translate a utilization headline directly into a census forecast or a reimbursement estimate. Management would need to compare its own payer mix with Medicare Advantage referral volume, admission conversion rates, authorization delays, length of stay, and denied or shortened coverage periods. Those measures are more useful than a national headline when setting staffing levels or evaluating expansion plans.

The same caution applies to quality benchmarking. Lower use does not automatically mean lower clinical need, better community alternatives, or worse access to post-acute rehabilitation. Those conclusions require data that is not present in the available evidence.

Prior authorization remains a separate pressure point

A related report from AOL.com describes bipartisan legislation introduced in Congress that would require Medicare Advantage plans to process standard prior authorizations within 72 hours. The proposal would permit extensions of up to seven days only in limited situations, require automated approval systems integrated with electronic health records, and restrict new authorization requirements for clinically necessary modifications or extensions during treatment.

The legislation is described as proposed, not enacted. Its operational significance is therefore prospective. If adopted, the requirements could change how SNFs document requests, monitor pending decisions, and escalate delayed determinations. The proposal would also require health plans to publish prior-authorization data, including processing times.

AOL.com further reports that a June Department of Health and Human Services inspector general report found high prior-authorization denial rates at UnitedHealthcare, CVS Health, and Humana for services including long-term acute care and inpatient rehabilitation. The source says some denial rates exceeded 70% in certain instances. Those figures concern the services described in that report and should not be recast as a national SNF denial rate.

What operators should verify before changing course

The immediate test is internal. Facilities should separate Medicare Advantage from traditional Medicare in their operating dashboards and track:

• referral-to-admission conversion;
• authorization turnaround time;
• requests for additional clinical records;
• denials, partial approvals, and stay extensions;
• discharge timing tied to coverage decisions; and
• accounts receivable by plan.

These measures can show whether lower Medicare Advantage SNF use is affecting a specific facility or market. They also expose where administrative friction is creating labor costs without producing reimbursable days.

Payers and providers should also distinguish authorization risk from reimbursement-threshold risk. A case can meet clinical admission criteria yet remain exposed to plan-specific approval rules, documentation requirements, or payment limits. Without plan-level data, national MedPAC findings cannot establish the financial effect on an individual nursing home.

The bottom line is narrow but consequential: AHCA/NCAL is pointing to lower SNF use among Medicare Advantage beneficiaries, while related reporting highlights authorization delays and proposed federal response. The evidence supports closer payer-level monitoring. It does not support a national utilization estimate, a causal explanation, or an immediate change to staffing and capital plans.